Gallium oxodotreotide
As of the edition of 20 October 2026, Gallium oxodotreotide is a protein: marketed, first approved in 2016 (US); no US protection of its own is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2016
- Kind
- Protein
- Brand name
- Netspot
- First approved
- 1 June 2016 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Univ Iowa Hosps And Clinics Pet Imaging Center; 2 holders in all
- Registered trials
- 36, 5 stopped early
- Disease areas
- Cancer; Hormones; Heart and blood vessels; Nervous system; Digestive system; Inherited and neonatal
US protection
No US protection of its own is listed.
The FDA registers list no drug-substance patent or exclusivity of its own that counts for this drug.
Univ Iowa Hosps And Clinics Pet Imaging Center holds a later exclusivity on its own new formulation or combination product, which ended in 2026; it does not protect the original drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 4 | 0 | 0 |
| Phase 1 | 13 | 2 | 5 | 2 |
| Phase 2 | 12 | 5 | 4 | 2 |
| Phase 3 | 5 | 2 | 2 | 1 |
| All trials | 36 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Univ Iowa Hosps And Clinics Pet Imaging Center | Later holder | 2019 to now |
| Novartis | Acquired holder and Lead sponsor of trials | 2024 to now |
| Advanced Accelerator Applications | Originator | 2016 to 2026 |